Schöne W, Ludwig M
Bezirkskrankenhaus für Neurologie u. Psychiatrie, Arnsdorf bei Dresden.
Fortschr Neurol Psychiatr. 1994 Sep;62 Suppl 1:16-8.
A 6-week double-blind, parallel group study compared paroxetine and fluoxetine in 106 depressed geriatric inpatients (aged 65 to 85 years). Patients presenting acutely with major depressive episode DSM-III-R 296.2 (HAMD > 18 on 21 item scale) were randomized to receive paroxetine (20-40 mg, n = 54) or fluoxetine (20-60 mg, n = 52) following a 3-7 day washout. Primary criteria was the reduction of Hamilton Depression Rating Scale Score (HAMD). Furthermore Montgomery-Asberg Depression Rating Scale (MADRS) and the Clinical Global Impression Scale (CGI) were used. Cognitive functions were assessed with the Mini-Mental-State Examination (MMSE) and the Sandoz Clinical Assessment Geriatric Scale (SCAG). The results showed a comparable reduction in the depression rating scales between the two treatment groups after 6 weeks. However, there was a statistically significant difference (p < 0.05) in HAMD, MADRS, SCAG, MMSE and cognitive subscales of HAMD and SCAG at week 3 in favour of paroxetine, which even was seen after 6 weeks in the SCAG. There were no significant differences between the treatment groups and the number of adverse events reported or in overall tolerability.
一项为期6周的双盲平行组研究,对106名老年抑郁症住院患者(年龄在65至85岁之间)使用帕罗西汀和氟西汀进行了比较。急性发作的重度抑郁发作DSM-III-R 296.2(21项量表上汉密尔顿抑郁量表评分>18)患者,在经过3至7天的洗脱期后,被随机分配接受帕罗西汀(20 - 40毫克,n = 54)或氟西汀(20 - 60毫克,n = 52)治疗。主要标准是汉密尔顿抑郁量表评分(HAMD)降低。此外,还使用了蒙哥马利-阿斯伯格抑郁量表(MADRS)和临床总体印象量表(CGI)。认知功能通过简易精神状态检查表(MMSE)和桑多兹老年临床评估量表(SCAG)进行评估。结果显示,6周后两个治疗组在抑郁量表评分上的降低程度相当。然而,在第3周时,帕罗西汀在HAMD、MADRS、SCAG、MMSE以及HAMD和SCAG的认知子量表方面有统计学显著差异(p < 0.05),在SCAG方面,6周后仍可见此差异。治疗组之间在报告的不良事件数量或总体耐受性方面没有显著差异。